2016 AHA Statin Drug Interactions Q1

2016 AHA Statin Drug Interactions

According to the 2016 AHA Scientific Statement:
“Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease” p e469

“DDIs involving the CYP450 enzyme system are generally classified as inhibition or induction interactions …┬áRegardless of the underlying mechanism, enzyme inhibition produces _______ serum concentrations of 1 or both medications. In the case of statin DDIs, the result is most often an _______ in statin serum concentrations.”

a) decreased ; decrease
b) decreased ; increase
c) increased ; increase
d) increased ; decrease

click here for answer

(C)

“DDIs involving the CYP450 enzyme system are generally classified as inhibition or induction interactions. Enzyme inhibition may occur as a result of direct competition by substrates for available binding sites, reduced enzymatic activity, or both. The onset of enzyme inhibition usually occurs rapidly after the introduction of an interacting drug. Direct competition is the most common mechanism resulting in DDIs and often occurs when 1 drug has a higher binding affinity for the enzyme or is present in significantly greater concentrations than its competing substrate. In contrast, some drugs may bind irreversibly to the enzyme and prevent its participation in subsequent metabolic reactions. Regardless of the underlying mechanism, enzyme inhibition produces increased serum concentrations of 1 or both medications. In the case of statin DDIs, the result is most often an increase in statin serum concentrations.”

Leave Comment

Your email address will not be published. Required fields are marked *